Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership is celebrating 20 years in business
Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus...
Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...
Research Partnership announces several new appointments
Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.
PMRC San Francisco 2017
We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research...
EphMRA Annual Conference 2017
Visit us on stand number 14
Richard Head nominated for EphMRA Award
We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...
Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report
Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...
EULAR Annual European Congress of Rheumatology 2017
Join us at EULAR Congress 2017 in Madrid, 14-17 June
PEGASUS UNVEILS NEW BRAND IDENTITY AS IT CELEBRATES A YEAR AS PART OF ASHFIELD
Pegasus, an Ashfield company, part of UDG Healthcare plc, has unveiled a new brand identity signaling its successful integration with the global business, a year on from acquisition. Conceived by...